AOP3DEBUNKS EVERYTHING: A Comprehensive Investigation into Risankizumab (Skyrizi) for Psoriasis Management
aop3d tech
Share
AOP3DEBUNKS EVERYTHING: A Comprehensive Investigation into Risankizumab (Skyrizi) for Psoriasis Management
1. Introduction: The Paradigm Shift in Psoriasis Care
1.1 The Evolution of Psoriasis Management
Psoriasis has historically been misunderstood, often dismissed as a mere cosmetic nuisance or a contagious skin infection. These misconceptions, deep-rooted in societal ignorance, have perpetuated a stigma that significantly impacts the quality of life for millions of sufferers worldwide. For decades, the medical community’s understanding of psoriasis was limited to its cutaneous manifestations—erythematous, scaly plaques resulting from hyperproliferation of keratinocytes. Consequently, treatment was largely confined to topical applications, phototherapy, and broad-spectrum systemic immunosuppressants like methotrexate and cyclosporine, which, while moderately effective, carried significant risks of organ toxicity and often failed to achieve complete clearance.
The dawn of the biologic era marked a seismic shift in dermatology. The realization that psoriasis is not merely a skin disease but a systemic, immune-mediated inflammatory disorder involving complex cytokine networks revolutionized therapeutic approaches. We have moved from an era where "control" was the goal—defined loosely as making the plaques manageable—to an era where "clearance" (complete absence of disease) is a realistic and expected outcome.
This report serves as a rigorous, evidence-based investigation into one of the newest and most potent agents in this class: Risankizumab (Skyrizi). Commissioned under the directive of "AOP3DEBUNKS EVERYTHING," this document scrutinizes the mechanism, efficacy, safety, and long-term implications of this drug. We will deconstruct the marketing claims, analyze the raw clinical trial data, and address the existential anxieties of patients: Is this a lifelong sentence? Does the disease return with a vengeance if you stop? And ultimately, is the clearance worth the cost and potential biological trade-offs?
1.2 Defining the Burden of Disease
To evaluate the efficacy of any drug, one must first understand the enemy it fights. Psoriasis is a chronic, relapsing-remitting autoimmune disease. It is characterized by the rapid overproduction of skin cells, driven by a malfunctioning immune system that mistakes healthy skin cells for pathogens.
Table 1: The Systemic Burden of Psoriasis
Domain
Impact & Comorbidities
Dermatological
Painful, itchy, scaly plaques; cracking and bleeding skin; nail dystrophy.
Musculoskeletal
Psoriatic Arthritis (PsA) affects up to 30% of patients, causing joint destruction and permanent disability.
Cardiovascular
Systemic inflammation contributes to endothelial dysfunction, increasing risks of hypertension, myocardial infarction, and stroke.
Metabolic
Strong associations with obesity, Type 2 diabetes, and non-alcoholic fatty liver disease.
Psychological
High prevalence of depression, anxiety, social isolation, and suicidal ideation due to visible stigma.
The systemic nature of the disease underscores why topical treatments are often insufficient for moderate-to-severe cases and why systemic biologic intervention is necessary not just for skin clearance, but for overall health preservation.
1.3 The Objective of This Investigation
This report addresses specific user-generated queries regarding Risankizumab:
Mechanism of Action: How exactly does it clear the skin?
The "Lifelong" Claim: Is it true that therapy must continue indefinitely?
Relapse Dynamics: What are the statistical odds of recurrence upon cessation?
Risk-Benefit Analysis: Do the potential side effects outweigh the benefits of clearance?
By synthesizing data from pivotal Phase 3 and 4 clinical trials (UltIMMa, IMMvent, LIMMitless), pharmacological reviews, and real-world patient registries, we provide a definitive, "debunking" style analysis of the current state of psoriasis management with IL-23 inhibitors.
2. Molecular Mechanism: How Skyrizi Clears the Skin
The user explicitly asks for a description of how the drug clears the skin. To answer this, we must descend into the immunopathogenesis of the psoriatic plaque. The effectiveness of Risankizumab lies in its precision; unlike older drugs that carpet-bombed the immune system, Skyrizi acts as a sniper targeting a specific communication node: the IL-23/Th17 axis.
2.1 The IL-23/Th17 Axis: The Engine of Psoriasis
In a healthy immune system, the body utilizes cytokines (chemical messengers) to coordinate defense against bacteria, fungi, and viruses. In psoriasis, this communication network is hijacked.
The Trigger: An initial trigger (genetic, environmental, or stress-related) activates dendritic cells in the skin and lymph nodes.
The Messenger (IL-23): These activated dendritic cells secrete excessive amounts of Interleukin-23 (IL-23). IL-23 is a heterodimeric cytokine, meaning it is built from two protein subunits: p19 and p40.
The Effectors (Th17 Cells): IL-23 binds to receptors on the surface of naïve T-cells, instructing them to differentiate into T-helper 17 (Th17) cells. These Th17 cells are the primary drivers of psoriatic inflammation.
The Attack (IL-17 & IL-22): Once activated, Th17 cells migrate to the dermis and release a barrage of inflammatory cytokines, specifically IL-17A, IL-17F, and IL-22.
The Consequence: These downstream cytokines act directly on keratinocytes (skin cells), forcing them to proliferate uncontrollably (hyperplasia) and preventing them from maturing properly (parakeratosis). This results in the thickening of the skin (plaque formation) and the shedding of immature cells (scaling).
2.2 Risankizumab: Selective p19 Inhibition
Risankizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Its mechanism of action is defined by its ability to bind with high affinity to the p19 subunit of IL-23.
The Critical Distinction: p19 vs. p40 Understanding why Risankizumab targets p19 is crucial for "debunking" fears about immune destruction.
Older Biologics (e.g., Ustekinumab): Targeted the p40 subunit. However, the p40 subunit is shared by two cytokines: IL-23 and IL-12. IL-12 is responsible for Th1 immune responses, which are critical for fighting intracellular pathogens (like TB) and for cancer surveillance. By blocking p40, older drugs inhibited both IL-23 (psoriasis driver) and IL-12 (protective immunity).
Risankizumab (Skyrizi): Targets p19, which is unique to IL-23. By targeting p19, Risankizumab inhibits the pathogenic IL-23/Th17 pathway without interfering with the IL-12/Th1 pathway.
Mechanism of Clearance: When Risankizumab binds to the p19 subunit of extracellular IL-23, it sterically hinders the cytokine from docking with the IL-23 receptor on the T-cell surface. This blockade breaks the cycle:
Blockade: IL-23 cannot signal naïve T-cells.
Starvation: Existing Th17 cells lose their survival signal and decline in number.
Normalization: The production of IL-17 and IL-22 drops precipitously.
Resolution: Without the inflammatory drive, keratinocytes return to a normal replication cycle (approx. 28 days). The plaques thin, the redness fades as inflammation subsides, and the skin clears.
2.3 Pharmacokinetics and Dosing Rationale
The structural engineering of Risankizumab also contributes to its efficacy profile. The antibody contains mutations in its Fc region (Leu234Ala and Leu235Ala) designed to reduce interactions with Fc gamma receptors, minimizing off-target inflammation.
Dosing Schedule:
Induction: Two starter doses at Week 0 and Week 4.
Maintenance: One dose every 12 weeks thereafter.
Half-Life: Approximately 28 days.
This long half-life allows for infrequent dosing (4 times per year), which improves patient adherence compared to older therapies requiring weekly or bi-weekly injections.
## 3. Clinical Efficacy: Validating the "Clear Skin" Claims
The user asks if the drug "clears the skin." To answer this scientifically, we analyze the clinical trial endpoints: PASI 90 (90% improvement, considered "Clear or Almost Clear") and PASI 100 (100% improvement, "Completely Clear").
3.1 The UltIMMa-1 and UltIMMa-2 Trials
These pivotal Phase 3, randomized, double-blind, placebo-controlled, and active comparator-controlled trials established the baseline efficacy of Risankizumab.
Table 2: Integrated Efficacy Results at Week 16 and Week 52
Endpoint
Week 16 (Risankizumab)
Week 16 (Placebo)
Week 16 (Ustekinumab)
Week 52 (Risankizumab)
Week 52 (Ustekinumab)
PASI 90
75.3%
4.9%
42.0%
81-82%
44.0%
PASI 100
36-51%
2.0%
24.0%
56-60%
30.0%
sPGA 0/1
84-88%
7.0%
63.0%
86%
54%
Data derived from integrated analyses of UltIMMa-1 and UltIMMa-2.
Analysis:
Rapid Onset: By Week 16 (after only two doses), three-quarters of patients achieved PASI 90. This confirms the claim that the drug acts relatively quickly to clear significant disease burden.
Superiority: Risankizumab demonstrated statistically significant superiority over Ustekinumab (Stelara), the previous gold standard for IL-12/23 inhibition. This validates the hypothesis that selective p19 inhibition is more effective than p40 inhibition.
Deepening Response: Crucially, response rates increased between Week 16 and Week 52. PASI 100 rates jumped from ~40% to ~60%. This indicates that the drug’s efficacy does not plateau early; skin continues to improve with sustained treatment.
3.2 Head-to-Head: Skyrizi vs. Humira (IMMvent Study)
To further debunk the efficacy of older biologic classes, the IMMvent study compared Risankizumab directly against Adalimumab (Humira), a TNF inhibitor.
Week 16 Results: 72% of Risankizumab patients achieved PASI 90 compared to only 47% of Adalimumab patients.
The Switch: Patients who did not achieve a PASI 90 response on Humira by Week 16 were re-randomized. Half switched to Skyrizi, half stayed on Humira.
Result of Switching: Of those who switched to Skyrizi, 66% subsequently achieved PASI 90.
Result of Staying: Of those who stayed on Humira, only 21% eventually achieved PASI 90.
Insight: This data strongly suggests that Skyrizi is effective even in patients who have failed other biologics. It rescues non-responders, validating its role as a high-efficacy option for refractory disease.
3.3 Long-Term Durability (LIMMitless Study)
The LIMMitless open-label extension study provides data out to nearly 6 years (304 weeks), addressing the "lifelong" efficacy question.
PASI 90 at Week 304: 86.0%
PASI 100 at Week 304: 54.2%.
Debunking Tolerance: A common myth is that biologics inevitably stop working as the body builds immunity to them (immunogenicity). The stability of these numbers over 6 years suggests that resistance to Risankizumab is extremely rare. Patients who get clear tend to stay clear as long as they remain on therapy.
4. Addressing the "Lifelong" Claim: Relapse and Withdrawal
The user explicitly asks: "Claims have been made that you need to take it for life or the psoriasis can come back is that true? If so what are the odds of it coming back?" This is the crux of the investigation.
4.1 The Verdict: True, But Nuanced
Claim: "You need to take it for life." Verdict: TRUE, in the context of maintaining clearance. Psoriasis is a chronic, genetically determined autoimmune disease. There is currently no cure that permanently rewires the immune system to stop the disease without ongoing suppression. Therefore, cessation of therapy removes the "brake" on the IL-23 pathway, and the inflammatory cycle eventually resumes.
4.2 Relapse Odds and Timeline
If a patient stops taking Skyrizi, will the psoriasis return?
The Odds: High. In a study analyzing relapse after discontinuation, 90.5% of patients eventually experienced a relapse (defined as loss of 50% of PASI improvement).
The Timeline: The median time to relapse (Drug-Free Remission or DFR) is approximately 104 days (roughly 15 weeks) after the last dose.
Comparison: This is superior to other biologics. Guselkumab has a median DFR of ~49 days; Mirikizumab ~79 days; and Secukinumab relapse can occur within 4-8 weeks.
Why the delay? Risankizumab has a long terminal half-life (~28 days). It takes roughly 4 to 5 half-lives for the drug to be completely eliminated from the body.
Calculation: 28 days x 5 = 140 days (approx. 4.5 months). This pharmacokinetic profile provides a "safety buffer." If a patient misses a dose by a few weeks, they are unlikely to flare immediately. The "crash" is slow, not sudden.
4.3 Debunking the "Rebound" Myth
Myth: "If I stop, it will come back worse than before." Fact: This phenomenon, known as the "Rebound Effect," is classically associated with systemic corticosteroids (like prednisone), where withdrawal can trigger erythrodermic or pustular psoriasis. Data on Skyrizi: Clinical trials indicate that while disease returns, it generally returns to its baseline severity over a period of months. It does not typically explode into a more severe form. The immune system slowly ramps the inflammation back up to its genetic set-point.
4.4 The "Super-Responder" Exception
Is it possible to stop and stay clear? Data: A small subset of patients, termed "Super-Responders," may achieve prolonged drug-free remission.
Characteristics: These patients typically have shorter disease duration (<2 years since diagnosis), are biologic-naive, and have lower baseline disease activity.
Hypothesis: Early intervention might modify the disease course by preventing the establishment of tissue-resident memory T-cells, though this remains theoretical.
Reality Check: While 10-20% of patients might sustain clearance for a year or more off-drug (data extrapolated from Secukinumab studies, as specific Risankizumab long-term withdrawal data is limited), the vast majority (90%) will relapse.
4.5 Retreatment Efficacy
If the disease returns, does the drug work again? Data: Yes. In the IMMvent study, patients who were withdrawn from treatment and allowed to relapse were retreated with Risankizumab. 84% of these patients regained their PASI 90 response. Implication: This debunks the fear that stopping the drug permanently breaks its efficacy. If a patient must pause (e.g., for surgery, pregnancy, or financial reasons), they can likely restart successfully.
5. Comprehensive Safety Analysis: Drawbacks and Side Effects
The user asks: "Is it worth taking skyrizi for the rest of your life? Let's cover some of the possible drawbacks and side effects!" A detailed risk-benefit analysis is required.
5.1 The Safety Profile: Overview
Because Risankizumab targets p19 (sparing IL-12), it leaves a significant portion of the immune system intact. This results in a safety profile that is generally considered superior to non-selective immunosuppressants (Methotrexate) and older biologics (TNF inhibitors).
Table 3: Common and Serious Adverse Events (AEs)
Adverse Event
Frequency
Mechanism/Context
Upper Respiratory Infection
Very Common (~13%)
Mild immune suppression allows common cold viruses to persist slightly longer.
Pneumonia, cellulitis. Rates are comparable to placebo in many analyses but vigilance is required.
5.2 Drawbacks: The Hidden Costs
Financial Toxicity:
Cost: The wholesale acquisition cost (WAC) is approximately $23,000 per dose (as of 2026 projections/current data), totaling nearly $92,000 annually for maintenance.
Access: Most insurance plans require "Step Therapy," forcing patients to fail cheaper drugs (methotrexate, Humira) before covering Skyrizi.
Implication: For those without robust insurance or access to the AbbVie "Bridge" programs, the drug is financially inaccessible.
Vaccination Restrictions:
Live Vaccines: Patients cannot receive live vaccines (MMR, Varicella, Yellow Fever, Intranasal Flu) while on therapy. This requires logistical planning for travel or childhood immunizations.
COVID-19/Flu: mRNA and inactivated vaccines are safe and recommended, though the antibody response might be slightly blunted.
Pregnancy and Lactation:
Data: There is limited data on Risankizumab in pregnancy. IgG antibodies are known to cross the placenta, particularly in the third trimester.
Guideline: Most dermatologists recommend discontinuing biologics during pregnancy unless the benefit clearly outweighs the risk, creating a difficult dilemma for women of childbearing age.
5.3 Debunking Serious Safety Myths
Myth: "It causes cancer." Investigation: TNF inhibitors (Humira) carry a "Black Box" warning for malignancy, specifically lymphoma. Skyrizi Reality: Long-term safety data (up to 5.9 years) shows no increased risk of malignancy compared to the general population. The rate of non-melanoma skin cancer (NMSC) was 0.6 events per 100 patient-years, consistent with background rates for psoriasis patients (who often have history of phototherapy).
Myth: "It causes depression." Investigation: Psoriasis causes depression. Skyrizi Reality: Clinical trials did not observe depression as a side effect. In fact, studies show that clearing the skin with biologics significantly improves anxiety and depression scores. By treating the disease, the mental health burden is alleviated.
Myth: "It destroys the liver." Investigation: Methotrexate is hepatotoxic. Skyrizi Reality: While liver enzymes are monitored, significant hepatotoxicity is rare. It is generally safe for patients with mild liver issues, unlike older systemic agents.
6. Comparative Analysis: Skyrizi vs. The Competition
To determine if Skyrizi is "worth it," we must compare it to the alternatives.
6.1 Skyrizi vs. Humira (Adalimumab)
Efficacy: Skyrizi is vastly superior (PASI 90: 75% vs 47%).
Dosing: Skyrizi is every 12 weeks; Humira is every 2 weeks.
Safety: Skyrizi lacks the Black Box warnings for cancer and serious infection that Humira carries. It also has lower rates of injection site pain (Humira is citrate-free now, but historically painful).
Verdict: Skyrizi is the clear clinical winner, though Humira remains a first-line insurance mandate due to low cost biosimilars.
Efficacy: Comparable at Week 16, but Skyrizi shows better long-term maintenance and durability.
Dosing: Skyrizi (4 shots/year) vs. Cosentyx (12 shots/year).
Side Effects: IL-17 inhibitors (Cosentyx) have a higher risk of Candida infections and can exacerbate Inflammatory Bowel Disease (IBD). Skyrizi is actually approved to treat Crohn's disease, making it the safer choice for patients with gut comorbidities.
6.3 Skyrizi vs. Otezla (Apremilast)
Type: Otezla is an oral pill (PDE4 inhibitor); Skyrizi is a biologic injection.
Efficacy: No contest. Skyrizi PASI 90 is ~72% vs Otezla's ~3% in head-to-head trials.
Safety: Otezla has GI side effects (diarrhea) and depression risks but no infection risk.
Verdict: Skyrizi is far more effective; Otezla is for needle-phobic patients with mild disease.
7. Patient Experience and "Worth It" Verdict
7.1 Real-World Perspectives
Patient narratives from forums and blogs highlight the transformative nature of the drug.
"Life-Changing": Stories emphasize the ability to wear shorts, swim, and date without shame—activities avoided for years.
The "OBI" Factor: For Crohn's patients (and potentially future PsO indications), the On-Body Injector (OBI) allows for home administration, further increasing convenience.
Anxiety: The primary patient anxiety reported is not the side effects, but the fear of insurance denial or losing coverage, reinforcing that the "financial side effect" is the most potent real-world stressor.
7.2 Is It Worth It? The Final Calculation
The decision to commit to lifelong therapy is personal, but the clinical data allows for an objective weighing of scales.
Reasons to say YES:
Unmatched Clearance: The probability of achieving completely clear skin (PASI 100) is higher with Skyrizi than almost any other drug in history.
Health Preservation: Treating the systemic inflammation likely lowers the risk of cardiovascular events and metabolic comorbidities associated with untreated psoriasis.
Convenience: 4 doses a year is a minimal lifestyle burden.
Safety: It offers one of the cleanest safety profiles of any systemic agent.
Reasons to Hesitate:
Cost: Without insurance, it is inaccessible.
Pregnancy: Women planning immediate conception may need alternative strategies.
Infection Risk: Those with chronic active infections (e.g., untreated HIV, Hep B) need careful management.
7.3 Conclusion
The investigation confirms that Risankizumab (Skyrizi) represents a pinnacle in psoriasis management. While the claim that "you must take it for life" is technically true for maintaining remission, the associated fear of "addiction" or "rebound" is largely unfounded. The drug clears skin through precise p19 inhibition, sparing the broader immune system and allowing for long-term safety. For the patient suffering from the physical and psychological torment of moderate-to-severe psoriasis, the evidence overwhelmingly suggests that the benefits of clearance justify the commitment to therapy.
Final Debunking Scorecard:
Claim: "Clears the skin." Verdict: TRUE (High efficacy).
Claim: "Take for life." Verdict: TRUE (Maintenance required).
Claim: "Dangerous side effects." Verdict: MOSTLY FALSE (Safety profile is robust; risks are rare/manageable).
Claim: "Rebound effect." Verdict: FALSE (Return is gradual).
Disclaimer: This report analyzes clinical data and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified dermatologist.
Works cited
1. 4 Common Myths About Psoriasis - Easton Dermatology Associates, https://www.eastondermatology.com/blog/4-common-myths-about-psoriasis 2. Debunking 6 Common Misconceptions About Psoriasis - CU Medicine, https://www.cumedicine.us/health-insights/debunking-6-common-misconceptions-about-psoriasis 3. Fact or Fiction? Debunking Common Myths About Psoriasis - Dermatology Associates of Atlanta, https://dermatlanta.com/blog/fact-or-fiction-debunking-common-myths-about-psoriasis/ 4. Anyone on Skyrizi? - Talk About Treatments - The Psoriasis Association, https://www.psoriasis-association.org.uk/forums/topic.aspx?ID=4309&page=3 5. Study Finds High Relapse Rate After Discontinuing PsO Biologics | Dermatology Times, https://www.dermatologytimes.com/view/study-finds-high-relapse-rate-after-discontinuing-pso-biologics 6. Risankizumab: Mechanism of action, clinical and translational science - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC10777435/ 7. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/ 8. Results - Clinical Review Report: Risankizumab (Skyrizi) - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK544852/ 9. Psoriasis Myths vs. Facts: What You Really Need to Know | Vanguard Skin Specialists, https://www.vanguardskin.com/psoriasis-myths-vs-facts-what-you-really-need-to-know/ 10. SKYRIZI® (risankizumab-rzaa) Mechanism of Action, https://www.skyrizihcp.com/dermatology/dosing/mechanism-of-action 11. Risankizumab vs. Ustekinumab for Psoriasis - YouTube, https://www.youtube.com/watch?v=uSZPplfbyGI 12. SKYRIZI® (risankizumab‐rzaa) vs Other Biologics, https://www.skyrizi.com/psoriasis/psoriasis-treatment/skyrizi-vs-other-biologics 13. How long does Skyrizi take to work? - Medical News Today, https://www.medicalnewstoday.com/articles/drugs-skyrizi-time-to-work 14. SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), https://www.skyrizihcp.com/dermatology/psoriasis-efficacy 15. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC9455321/ 16. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC7818271/ 17. Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies - PR Newswire, https://www.prnewswire.com/news-releases/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies-300543919.html 18. SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study - PR Newswire, https://www.prnewswire.com/news-releases/skyrizi-risankizumab-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-adult-patients-with-moderate-plaque-psoriasis-in-phase-4-head-to-head-study-301885778.html 19. SKYRIZI VS HUMIRA® (adalimumab) 2 SUPERIOR RATES OF PASI 90 AT WEEK 16 IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY, https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira 20. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11393235/ 21. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies | Clinical and Experimental Dermatology | Oxford Academic, https://academic.oup.com/ced/article/49/8/793/7307582 22. What Happens If I Stop Taking a Biologic Treatment for Psoriatic Arthritis? - Healthline, https://www.healthline.com/health/psoriatic-arthritis/stop-biologics-psoriatic-arthritis 23. Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study - MDPI, https://www.mdpi.com/2077-0383/14/18/6371 24. How to define a 'super-responder' to biologics in psoriasis studies - Oxford Academic, https://academic.oup.com/bjd/article-abstract/189/5/621/7245983 25. Associated risk factors and rate of relapse of plaque psoriasis following withdrawal of biologics - OpenBU, https://open.bu.edu/bitstreams/152855c1-32bf-451d-a9d2-74ae57ae64bc/download 26. SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile 27. SKYRIZI® (risankizumab-rzaa) Ps & PsA Cost, Savings, https://www.skyrizi.com/psoriasis-psoriatic-arthritis/cost-and-savings 28. SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, https://www.skyrizihcp.com/dermatology/coverage-access 29. How Much Is Skyrizi Without Insurance? - GoodRx, https://www.goodrx.com/skyrizi/how-much-is-skyrizi-without-insurance 30. SKYRIZI® (risankizumab-rzaa) | Receive Latest News and Information, https://www.skyrizihcp.com/registration 31. Important Safety Information | SKYRIZI® (risankizumab-rzaa), https://www.skyrizi.com/important-safety-information 32. IL-23 Inhibitors in Dermatology - Drug, Mechanism of Action, Use, Side-effects - YouTube, https://www.youtube.com/watch?v=KOINHHT8kf0 33. COVID-19 & SKYRIZI® (risankizumab-rzaa), https://www.skyrizihcp.com/dermatology/covid19.html 34. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11393270/ 35. Skyrizi: Side Effects and How to Manage Them - Healthgrades Health Library, https://resources.healthgrades.com/drugs/skyrizi-side-effects 36. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC9366680/ 37. Depression and Anxiety in Patients with Psoriasis: A Comprehensive Analysis Combining Bibliometrics, Latent Dirichlet Allocation, and HJ-Biplot - MDPI, https://www.mdpi.com/2227-9032/13/5/441 38. Skyrizi Side Effects: 7 Things to Look Out for - GoodRx, https://www.goodrx.com/skyrizi/common-side-effects 39. SKYRIZI® (risankizumab-rzaa) Side Effects, https://www.skyrizi.com/crohns/about-skyrizi/side-effects 40. Skyrizi vs. Humira Prescription Treatment for Plaque Psoriasis: Differences and Side Effects, https://www.rxlist.com/skyrizi_vs_humira/drugs-condition.htm 41. SKYRIZI® Psoriasis Results - SKYRIZI® (risankizumab‐rzaa), https://www.skyrizi.com/psoriasis/psoriasis-treatment/skyrizi-results 42. Kathryn Taking Transcript - SKYRIZI® (risankizumab-rzaa), https://www.skyrizi.com/crohns/skyrizi-results/patient-stories/kathryn-taking-transcript 43. The Patient Experience: What the IBD Community Has to Say About Skyrizi - lights camera crohn's, https://lightscameracrohns.com/2023/07/10/the-patient-experience-what-the-ibd-community-has-to-say-about-skyrizi/ 44. IL-23: Long-term Data and Safety Data | AJMC, https://www.ajmc.com/view/il-23-long-term-data-and-safety-data
Please read this disclaimer carefully before using AOP3D.COM (hereinafter referred to as "The Website," "we," "us," or "our"). By accessing or using this Website, you agree to be bound by the terms and conditions set forth below. If you do not agree with these terms, please do not use this Website.
1. Legal & Medical Disclaimer
The following is a mandatory condition of use for this Website:
This blog is For Informational Purposes Only: All information and resources found on this blog are based on the opinions of the author unless otherwise noted. All information is intended to encourage readers to make their own health and wellness decisions after consulting with their healthcare provider.
Not Medical Advice: The author of this blog is not a doctor. The information on this site is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Do not use this information to diagnose or treat any health problem without consulting a qualified healthcare provider. If you think you may have a medical emergency, call your doctor or 911 immediately.
No Liability: The author and publisher of this site are not responsible for any errors or omissions in any content herein. Reliance on any information appearing on this site is strictly at your own risk. By using this blog, you agree to these terms.
2. Professional Life Advice & Coaching Disclaimer
In addition to the medical disclaimer above, this Website discusses life advice, mental mindset, and personal development.
Not Professional Counseling: The content on this Website is for educational and entertainment purposes only. It does not constitute a professional-client relationship. The authors are not licensed psychologists, psychiatrists, or certified life coaches (unless explicitly stated on their specific author bio page).
Personal Responsibility: You acknowledge that you are participating voluntarily in using our Website and that you are solely and personally responsible for your choices, actions, and results, now and in the future. You accept full responsibility for the consequences of your use, or non-use, of any information provided on or through this Website.
3. Technology Reviews & Warranty Disclaimer
Our Website frequently reviews technology, software, and gadgets.
"As Is" Information: All reviews and tutorials are provided "as is" without warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose.
Rapidly Changing Industry: Technology changes rapidly. While we strive to keep our articles up to date, we cannot guarantee that information regarding specs, pricing, or software versions is accurate at the time you read it.
User Risk: We are not liable for any damage to your devices, loss of data, security breaches, or "bricking" of devices that may occur if you choose to follow our tutorials, download recommended software, or purchase hardware based on our reviews.
4. Apps, Widgets & Tools Disclaimer
In addition to written content, we may provide free apps, widgets, calculators, and downloadable software tools (collectively, "Tools") for your use.
"As Is" and "As Available": All Tools provided on this Website are offered on a strictly "as is" and "as available" basis. We make no representations or warranties of any kind, express or implied, regarding the compatibility, stability, or safety of these Tools.12
Use at Your Own Risk: You acknowledge that the installation and use of any Tools from this W3ebsi4te is done entirely at your own discretion and risk. You are solely responsible for adequate protection and backup of data and equipment used in connection with any of our Tools.
No Liability for Damages: We shall not be liable for any damages, including but not limited to direct, indirect, incidental, or consequential damages, loss of data, corruption of software, or hardware malfunction arising out of the use or inability to use our Tools.
4.1 Data Collection & Privacy for Apps and Widgets
While many of our widgets and tools are free to use without registration, you acknowledge that by using them, certain non-personal technical data may be automatically collected to ensure functionality.
Data Collected: When you use our calculators, widgets, or apps, our servers may log your IP address, browser type, and device information to prevent abuse and ensure the tool functions correctly.
Cookies: Our tools may use "cookies" or local storage to save your preferences (e.g., saving your place in a calculator). These are stored locally on your device.
No Sale of Data: We do not sell the data entered into our widgets to third parties. However, we cannot guarantee the security of data transmitted over the internet; do not enter sensitive personal or financial information (like Social Security numbers or credit card details) into our free public widgets.
5. Debunking & Fact-Checking Policy
A portion of this Website is dedicated to investigating claims and debunking myths.
Opinion vs. Fact: While we strive for high journalistic standards and cite sources where possible, our analysis constitutes our opinion based on the available evidence at the time of writing.
No Defamation Intended: Commentary regarding public figures, companies, or other entities is made under the doctrine of Fair Comment and constitutes criticism and review. It is not intended to malign any religion, ethnic group, club, organization, company, or individual.
Right to Retract: We reserve the right to change, update, or retract information if new evidence comes to light.
6. Affiliate & Advertising Disclosure
FTC Disclosure: In compliance with the Federal Trade Commission (FTC) guidelines, please assume that any external links on this Website are "affiliate links." This means that if you click on a link and buy a product, we may receive a small commission at no extra cost to you. This helps support our blog and allows us to continue making free content.
Amazon Associates Disclosure: [Insert Your Website Name] is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. As an Amazon Associate, we earn from qualifying purchases.
Unbiased Reviews: Please note that while we may receive commissions, our reviews and debunking articles are based on our honest opinions, findings, beliefs, and experiences. We do not accept money to write positive reviews.
7. Errors and Omissions
The information contained in this Website is for general information purposes only. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the Website or the information, products, services, or related graphics contained on the Website for any purpose.
One Final Step for You
If you are using Amazon Associates, their rules require you to have a small sentence visible on every page (usually in the Footer), not just on this dedicated disclaimer page.
Would you like the short "Footer Sentence" that you can paste into your site's main footer to handle that requirement?
aop3d.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. As an Amazon Associate, we earn from qualifying purchases.
All content provided is for informational purposes only and is not intended as medical or professional advice. Use of our apps and widgets is at your own risk.
Choosing a selection results in a full page refresh.
